Reuters logo
a month ago
BRIEF-Syndax Pharmaceuticals says preclinical results support Entinostat's role in targeting tumor microenvironment
July 11, 2017 / 8:19 PM / a month ago

BRIEF-Syndax Pharmaceuticals says preclinical results support Entinostat's role in targeting tumor microenvironment

July 11 (Reuters) - Syndax Pharmaceuticals Inc:

* Syndax Pharmaceuticals Inc says preclinical results support Entinostat's role in targeting tumor microenvironment to enhance immune checkpoint therapy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below